Kairos Pharma, Ltd. (KAPA) Price & Analysis

Compare

121 Followers

KAPA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.40 - $3.25

Previous CloseN/A

Volume680.77K

Average Volume (3M)1.56M

Market Cap

$25.31M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.40

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding20,743,765

10 Day Avg. Volume2,076,440

30 Day Avg. Volume1,564,914

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$8.00

Price Target Upside555.74% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsKairos announced positive interim efficacy data from the ongoing P2 trial evaluating ENV-105 + Erleada in 2L metastatic castration-resistant prostate cancer (mCRPC) patients.

Safety DataPositive interim safety update from the ongoing randomized Phase 2 study of its lead asset, ENV-105, in patients with metastatic castration resistant prostate cancer.

Stock PerformanceKAPA shares have increased by over 150% since early June, attributed to positive P2 safety results, a strong biotech sector performance, and anticipation of interim data in prostate cancer.

Bears Say

Financial PerformanceKairos announced 2Q25 financial results, posting EPS of ($0.08), compared to our estimate of ($0.06), and consensus of ($0.05).

Stock DeclineKAPA shares are down ~16% on the news, which is believed to stem from the recent run-up.

Kairos Pharma, Ltd. News

Kairos Pharma announces interim efficacy analysis of ENV105

Kairos Pharma (KAPA) announced efficacy data from its ongoing Phase 2 clinical trial of ENV105 in patients with...

2d ago

KAPA

Kairos Pharma Reports Positive Phase 2 Trial Results

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an update. On September 18, 2025, Kairos Pharma announced positive...

2d ago

KAPA

Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Kairos Pharma, Ltd., retaining the price target...

3d ago

KAPA

Kairos Pharma to Host KOL Event on Phase 2 Trial

Kairos Pharma, Ltd. ( ($KAPA) ) has shared an announcement. On September 11, 2025, Kairos Pharma announced it...

9d ago

KAPA

Kairos Pharma Presents Phase 1 Data at Conference

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On September 3, 2025, Kairos Pharma announced its...

17d ago

KAPA

Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Kairos Pharma, Ltd.. The associated price...

1M ago

KAPA

Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kairos Pharma, Ltd.,...

1M ago

KAPA

Kairos Pharma management to meet with Maxim

Meeting to be held on August 6 hosted by Maxim. Published first on TheFly – the ultimate source...

2M ago

KAPA

Why Is Kairos Pharma Stock (KAPA) Up 170% Today?

Kairos Pharma stock rallied on Tuesday after it posted positive interim safety results from a clinical trial. ...

2M ago

KAPA

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Traders looking for all of Tuesday’s hottest stock market news will find it at TipRanks! ...

2M ago

AMD

Promising Potential for Kairos Pharma’s ENV-105: Positive Safety Profile and Efficacy Outlook

Kairos Pharma, Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

2M ago

KAPA

Kairos Pharma Announces Positive Phase 2 Trial Results

Kairos Pharma, Ltd. ( ($KAPA) ) has provided an update. On July 15, 2025, Kairos Pharma, Ltd. announced...

2M ago

KAPA

Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial

Kairos Pharma (KAPA) announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients...

2M ago

KAPA

Kairos Pharma files to sell 16.29M shares of common stock for holders

06:05 EDT Kairos Pharma (KAPA) files to sell 16.29M shares of common stock for holders Published first on...

5M ago

KAPA

KAPA FAQ

What was Kairos Pharma, Ltd.’s price range in the past 12 months?

Kairos Pharma, Ltd. lowest stock price was $0.40 and its highest was $3.25 in the past 12 months.

What is Kairos Pharma, Ltd.’s market cap?

Kairos Pharma, Ltd.’s market cap is $25.31M.

When is Kairos Pharma, Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kairos Pharma, Ltd.’s earnings last quarter?

Currently, no data Available

Is Kairos Pharma, Ltd. overvalued?

According to Wall Street analysts Kairos Pharma, Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kairos Pharma, Ltd. pay dividends?

Kairos Pharma, Ltd. does not currently pay dividends.

What is Kairos Pharma, Ltd.’s EPS estimate?

Kairos Pharma, Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kairos Pharma, Ltd. have?

Kairos Pharma, Ltd. has 20,743,765 shares outstanding.

What happened to Kairos Pharma, Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kairos Pharma, Ltd.?

Currently, no hedge funds are holding shares in KAPA

Company Description

Kairos Pharma, Ltd.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Kairos Pharma, Ltd. (KAPA) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

KAPA Stock 12 Month Forecast

Average Price Target

$8.00

▲(555.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","-1":"-$1","2.5":"$2.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.5,6,9.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Oct<br/>2024","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,2.2246153846153844,3.039230769230769,3.8538461538461535,4.668461538461538,5.483076923076923,6.297692307692308,7.112307692307692,7.926923076923077,8.741538461538461,9.556153846153846,10.37076923076923,11.185384615384615,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,1.916923076923077,2.4238461538461538,2.930769230769231,3.4376923076923074,3.9446153846153846,4.451538461538462,4.958461538461538,5.4653846153846155,5.972307692307693,6.479230769230769,6.986153846153846,7.493076923076924,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,1.609230769230769,1.8084615384615383,2.0076923076923077,2.2069230769230765,2.406153846153846,2.605384615384615,2.804615384615384,3.003846153846154,3.2030769230769227,3.402307692307692,3.6015384615384614,3.8007692307692302,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.46,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >